NSAIDs, like piroxicam, are preferred to be the “first-line” therapeutic drugs for the treatment of RA, as they restrict the upregulation of IL-6, IL-1, TNF-α, and pro-inflammatory prostaglandins by blocking the cyclooxygenase pathway of the arachidonic acid cascade. This evidence concerns the gene IL6 and rheumatoid arthritis.